PlaqueTec

Executive Summary

PlaqueTec is a Cambridge, UK-based diagnostics company pioneering biomarker-based cardiovascular personalized medicine. Its novel Liquid Biopsy System aims to transform prevention, diagnosis, and treatment of coronary artery disease (CAD), the world's leading cause of death. By analyzing blood-based biomarkers, the platform promises to identify high-risk plaques and guide therapeutic decisions, moving beyond traditional imaging and risk scores. Founded in 2014, PlaqueTec operates in the early-stage diagnostics space with no disclosed funding or revenue. The company's technology addresses a critical unmet need for precision medicine in cardiology, potentially improving outcomes and reducing healthcare costs. While still pre-commercial, its clinical validation progress and strategic partnerships will be key to success.

Upcoming Catalysts (preview)

• Q4 2026Clinical Data Readout from Liquid Biopsy Validation Study60% success
• Q2 2027Series B or C Funding Round Closure50% success
• Q3 2027CE Marking or FDA Breakthrough Device Designation40% success